Increasing LH pulsatility in women with hypothalamic amenorrhoea using intravenous infusion of Kisspeptin-54

CN Jayasena, A Abbara, JD Veldhuis… - The Journal of …, 2014 - academic.oup.com
CN Jayasena, A Abbara, JD Veldhuis, AN Comninos, R Ratnasabapathy, A De Silva…
The Journal of Clinical Endocrinology & Metabolism, 2014academic.oup.com
Background: Hypothalamic amenorrhea (HA) is the one of the most common causes of
period loss in women of reproductive age and is associated with deficient LH pulsatility.
High-dose kisspeptin-54 acutely stimulates LH secretion in women with HA, but chronic
administration causes desensitization. GnRH has paradoxical effects on reproductive
activity; we therefore hypothesized that a dose-dependent therapeutic window exists within
which kisspeptin treatment restores the GnRH/LH pulsatility in women with HA. Aim: The aim …
Background
Hypothalamic amenorrhea (HA) is the one of the most common causes of period loss in women of reproductive age and is associated with deficient LH pulsatility. High-dose kisspeptin-54 acutely stimulates LH secretion in women with HA, but chronic administration causes desensitization. GnRH has paradoxical effects on reproductive activity; we therefore hypothesized that a dose-dependent therapeutic window exists within which kisspeptin treatment restores the GnRH/LH pulsatility in women with HA.
Aim
The aim of the study was to determine whether constant iv infusion of kisspeptin-54 temporarily increases pulsatile LH secretion in women with HA.
Methods
Five patients with HA each underwent six assessments of LH pulsatility. Single-blinded continuous iv infusion of vehicle or kisspeptin-54 (0.01, 0.03, 0.10, 0.30, or 1.00 nmol/kg/h) was administered. The LH pulses were detected using blinded deconvolution.
Results
Kisspeptin increased LH pulsatility in all patients with HA, with peak responses observed at different doses in each patient. The mean peak number of pulses during infusion of kisspeptin-54 was 3-fold higher when compared with vehicle (number of LH pulses per 8 h: 1.6 ± 0.4, vehicle; 5.0 ± 0.5, kisspeptin-54, P < .01 vs vehicle). The mean peak LH pulse secretory mass during kisspeptin-54 was 6-fold higher when compared with vehicle (LH pulse secretory mass in international units per liter: 3.92 ± 2.31, vehicle; 23.44 ± 12.59, kisspeptin-54; P < .05 vs vehicle).
Conclusions
Kisspeptin-54 infusion temporarily increases LH pulsatility in women with HA. Furthermore, we have determined the dose range within which kisspeptin-54 treatment increases basal and pulsatile LH secretion in women with HA. This work provides a basis for studying the potential of kisspeptin-based therapies to treat women with HA.
Oxford University Press